Oxprenolol (BioDeep_00000018096)

   

human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds


代谢物信息卡片


1-[2-(prop-2-en-1-yloxy)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol

化学式: C15H23NO3 (265.1677848)
中文名称: 氧烯洛尔
谱图信息: 最多检出来源 Homo sapiens(blood) 96.01%

分子结构信息

SMILES: C=CCOc1ccccc1OCC(O)CNC(C)C
InChI: InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3

描述信息

Oxprenolol is only found in individuals that have used or taken this drug. It is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms, anxiety, and high blood pressure. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water-soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than beta blockers with more hydrophilic molecules such as atenolol, sotalol, and nadolol (Wikipedia). Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol, therefore, inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

同义名列表

19 个代谢物同义名

1-[2-(prop-2-en-1-yloxy)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol; 1-(Isopropylamino)-2-hydroxy-3-(O-(allyloxy)phenoxy)propane; (1)-1-(O-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+)-1-(O-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol; 1-(O-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; Hydrochloride, oxprenolol; OXPRENOLOL HYDROCHLORIDE; (+-)-Oxprenolol; Trasicor, slow; Slow trasicor; DL-Oxprenolol; Osprenololo; oxprenolol; Trasicor; Tevacor; Coretal; Koretal; Oxprenolol



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mariusz Stolarczyk, Anna Apola, Anna Malanka, Anna Kwiecien, Edyta Wrona, Wlodzimierz Opoka. DETERMINATION OF SOTALOL, OXPRENOLOL AND LABETALOL IN BINARY MIXTURES AND IN SPIKED HUMAN SERUM BY DERIVATIVE SPECTROPHOTOMETRIC METHOD. Acta poloniae pharmaceutica. 2017 Jan; 74(1):93-102. doi: . [PMID: 29474765]
  • Khaled Azizi, Mokhtar Ganjali Koli. Molecular dynamics simulations of Oxprenolol and Propranolol in a DPPC lipid bilayer. Journal of molecular graphics & modelling. 2016 Mar; 64(?):153-164. doi: 10.1016/j.jmgm.2016.01.009. [PMID: 26851866]
  • Mariane Gonçalves Santos, Gabriel de Oliveira Isac Moraes, Maurício Gustavo Nakamura, Álvaro José dos Santos-Neto, Eduardo Costa Figueiredo. Restricted access molecularly imprinted polymers obtained by bovine serum albumin and/or hydrophilic monomers' external layers: a comparison related to physical and chemical properties. The Analyst. 2015 Nov; 140(22):7768-75. doi: 10.1039/c5an01482d. [PMID: 26460233]
  • Gesche Först, Lukasz Cwiklik, Piotr Jurkiewicz, Rolf Schubert, Martin Hof. Interactions of beta-blockers with model lipid membranes: molecular view of the interaction of acebutolol, oxprenolol, and propranolol with phosphatidylcholine vesicles by time-dependent fluorescence shift and molecular dynamics simulations. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2014 Aug; 87(3):559-69. doi: 10.1016/j.ejpb.2014.03.013. [PMID: 24681296]
  • Sonia Amores, Jacinto Lauroba, Ana Calpena, Helena Colom, Alvaro Gimeno, José Domenech. A comparative ex vivo drug permeation study of beta-blockers through porcine buccal mucosa. International journal of pharmaceutics. 2014 Jul; 468(1-2):50-4. doi: 10.1016/j.ijpharm.2014.03.050. [PMID: 24727142]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Yue Jin, Cheng Chen, Lingchen Meng, Jitao Chen, Meixian Li, Zhiwei Zhu. Simultaneous and sensitive capillary electrophoretic enantioseparation of three β-blockers with the combination of achiral ionic liquid and dual CD derivatives. Talanta. 2012 Jan; 89(?):149-54. doi: 10.1016/j.talanta.2011.12.005. [PMID: 22284473]
  • Maki Mizogami, Ko Takakura, Hironori Tsuchiya. The interactivities with lipid membranes differentially characterize selective and nonselective beta1-blockers. European journal of anaesthesiology. 2010 Sep; 27(9):829-34. doi: 10.1097/eja.0b013e32833bf5e4. [PMID: 20601889]
  • S A B Salman, S A Sulaiman, Z Ismail, S H Gan. Quantitative determination of propranolol by ultraviolet HPLC in human plasma. Toxicology mechanisms and methods. 2010 Mar; 20(3):137-42. doi: 10.3109/15376511003602112. [PMID: 20128736]
  • Markus Fridén, Susanne Winiwarter, Gunilla Jerndal, Ola Bengtsson, Hong Wan, Ulf Bredberg, Margareta Hammarlund-Udenaes, Madeleine Antonsson. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. Journal of medicinal chemistry. 2009 Oct; 52(20):6233-43. doi: 10.1021/jm901036q. [PMID: 19764786]
  • Bogusław Buszewski, Tomasz Welerowicz, Eugenia Tegowska, Tadeusz F Krzemiński. Determination of selected beta-receptor antagonists in biological samples by solid-phase extraction with cholesterolic phase and LC/MS. Analytical and bioanalytical chemistry. 2009 Jan; 393(1):263-72. doi: 10.1007/s00216-008-2369-1. [PMID: 18781297]
  • Giovanni D'Orazio, Salvatore Fanali. Enantiomeric separation by using nano-liquid chromatography with on-column focusing. Journal of separation science. 2008 Aug; 31(14):2567-71. doi: 10.1002/jssc.200800114. [PMID: 18623279]
  • Guoqiang Yang, Yifang Zhao, Meixian Li, Zhiwei Zhu, Qiankun Zhuang. Study on chiral resolution of three beta-blockers by affinity electrokinetic chromatography. Talanta. 2008 Mar; 75(1):222-6. doi: 10.1016/j.talanta.2007.11.007. [PMID: 18371871]
  • Antonella De Rossi, Claudia Desiderio. High sensitivity analysis of oxprenolol in urine by capillary electrophoresis with C18 packed on-line preconcentrator. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Jul; 839(1-2):6-11. doi: 10.1016/j.jchromb.2005.11.046. [PMID: 16364697]
  • Vlasta Bradamante, Zarka Krnić, Renata Zrinski, Pasko Konjevoda, Zeljko Reiner. Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats. Arzneimittel-Forschung. 2006; 56(2):64-9. doi: 10.1055/s-0031-1296703. [PMID: 16572919]
  • Maria A Martinez-Gomez, Rosa M Villanueva-Camañas, Salvador Sagrado, Maria J Medina-Hernández. Multivariate optimization approach for chiral resolution of drugs using human serum albumin in affinity electrokinetic chromatography-partial filling technique. Electrophoresis. 2005 Nov; 26(21):4116-26. doi: 10.1002/elps.200500304. [PMID: 16252317]
  • M A Martínez-Gómez, J J Martínez-Pla, S Sagrado, R M Villanueva-Camañas, M J Medina-Hernández. Chiral separation of oxprenolol by affinity electrokinetic chromatography-partial filling technique using human serum albumin as chiral selector. Journal of pharmaceutical and biomedical analysis. 2005 Sep; 39(1-2):76-81. doi: 10.1016/j.jpba.2005.03.028. [PMID: 15927439]
  • M I Maguregui, R M Jiménez, R M Alonso, U Akesolo. Quantitative determination of oxprenolol and timolol in urine by capillary zone electrophoresis. Journal of chromatography. A. 2002 Mar; 949(1-2):91-7. doi: 10.1016/s0021-9673(01)01320-6. [PMID: 11999762]
  • G Colmenarejo, A Alvarez-Pedraglio, J L Lavandera. Cheminformatic models to predict binding affinities to human serum albumin. Journal of medicinal chemistry. 2001 Dec; 44(25):4370-8. doi: 10.1021/jm010960b. [PMID: 11728183]
  • A J Dudley, K Bleasby, C D Brown. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. British journal of pharmacology. 2000 Sep; 131(1):71-9. doi: 10.1038/sj.bjp.0703518. [PMID: 10960071]
  • J Haginaka, H Matsunaga. Separation of enantiomers on HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein: effect of sugar moiety on chiral recognition ability. Enantiomer. 2000; 5(1):37-45. doi: NULL. [PMID: 10763868]
  • C L Kaul. Role of sympathetic nervous system in experimental hypertension and diabetes mellitus. Clinical and experimental hypertension (New York, N.Y. : 1993). 1999 Jan; 21(1-2):95-112. doi: 10.3109/10641969909068653. [PMID: 10052646]
  • M T am Ende, N A Peppa. FTIR spectroscopic investigation and modeling of solute/polymer interactions in the hydrated state. Journal of biomaterials science. Polymer edition. 1999; 10(12):1289-302. doi: 10.1163/156856299x00081. [PMID: 10673023]
  • A J Braza, P Modamio, E L Mariño. Determination of celiprolol and oxprenolol in human plasma by high-performance liquid chromatography and the analytical error function. Journal of chromatography. B, Biomedical sciences and applications. 1998 Nov; 718(2):267-72. doi: 10.1016/s0378-4347(98)00378-8. [PMID: 9840437]
  • C G Jordan. How an increase in the carbon chain length of the ester moiety affects the stability of a homologous series of oxprenolol esters in the presence of biological enzymes. Journal of pharmaceutical sciences. 1998 Jul; 87(7):880-5. doi: 10.1021/js970280p. [PMID: 9649358]
  • S E Leucuta, M Follidis, R Capalneanu, A Mocan. Relative bioavailability of different oral sustained release oxprenolol tablets. European journal of drug metabolism and pharmacokinetics. 1998 Apr; 23(2):178-84. doi: 10.1007/bf03189336. [PMID: 9725478]
  • Z Krnić, V Bradamante. Effects of oxprenolol treatment on pseudocholinesterase and lipids in rats. Arzneimittel-Forschung. 1997 Aug; 47(8):910-3. doi: NULL. [PMID: 9296276]
  • A Ceccato, B Toussaint, P Chiap, P Hubert, J Crommen. Enantioselective determination of oxprenolol in human plasma using dialysis coupled on-line to reversed-phase chiral liquid chromatography. Journal of pharmaceutical and biomedical analysis. 1997 Jun; 15(9-10):1365-74. doi: 10.1016/s0731-7085(96)01965-6. [PMID: 9226565]
  • F Mangani, G Luck, C Fraudeau, E Vérette. On-line column-switching high-performance liquid chromatography analysis of cardiovascular drugs in serum with automated sample clean-up and zone-cutting technique to perform chiral separation. Journal of chromatography. A. 1997 Feb; 762(1-2):235-41. doi: 10.1016/s0021-9673(96)00878-3. [PMID: 9098982]
  • T Seifert, O Zschörnig, J Arnhold, K Arnold. Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro. Chemistry and physics of lipids. 1997 Jan; 85(1):13-21. doi: 10.1016/s0009-3084(96)02637-0. [PMID: 9032944]
  • F T Delbeke. Disposition of human drug preparations in the horse. V. Orally administered oxprenolol. Biomedical chromatography : BMC. 1996 Jul; 10(4):172-8. doi: 10.1002/(sici)1099-0801(199607)10:4<172::aid-bmc588>3.0.co;2-1. [PMID: 8831961]
  • K Hartonen, M L Riekkola. Detection of beta-blockers in urine by solid-phase extraction-supercritical fluid extraction and gas chromatography-mass spectrometry. Journal of chromatography. B, Biomedical applications. 1996 Feb; 676(1):45-52. doi: 10.1016/0378-4347(95)00373-8. [PMID: 8852043]
  • M E Laethem, F M Belpaire, M G Bogaert. Direct high-performance liquid chromatography determination of diastereomeric oxprenolol glucuronides. Journal of chromatography. B, Biomedical applications. 1996 Jan; 675(2):251-5. doi: 10.1016/0378-4347(95)00358-4. [PMID: 8852712]
  • F Li, S F Cooper, S R Mikkelsen. Enantioselective determination of oxprenolol and its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Journal of chromatography. B, Biomedical applications. 1995 Dec; 674(2):277-85. doi: 10.1016/0378-4347(95)00307-x. [PMID: 8788157]
  • M E Laethem, F M Belpaire, P Wijnant, M G Bogaert. Effect of probenecid on the enantioselective pharmacokinetics of oxprenolol and its glucuronides in the rabbit. Pharmaceutical research. 1995 Dec; 12(12):1964-7. doi: 10.1023/a:1016204309083. [PMID: 8786974]
  • M E Laethem, R A Lefebvre, F M Belpaire, H L Vanhoe, M G Bogaert. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans. Clinical pharmacology and therapeutics. 1995 Apr; 57(4):419-24. doi: 10.1016/0009-9236(95)90211-2. [PMID: 7712670]
  • U Hellwich, R Schubert. Concentration-dependent binding of the chiral beta-blocker oxprenolol to isoelectric or negatively charged unilamellar vesicles. Biochemical pharmacology. 1995 Feb; 49(4):511-7. doi: 10.1016/0006-2952(94)00418-l. [PMID: 7872956]
  • M E Laethem, F M Belpaire, P Wijnant, M G Bogaert. Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin. Chirality. 1995; 7(8):616-22. doi: 10.1002/chir.530070811. [PMID: 8593255]
  • M E Laethem, F M Belpaire, P Wijnant, M T Rosseel, M G Bogaert. Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat. Chirality. 1994; 6(5):405-10. doi: 10.1002/chir.530060508. [PMID: 8068500]
  • M E Laethem, M T Rosseel, P Wijnant, F M Belpaire. Chiral high-performance liquid chromatographic determination of oxprenolol in plasma. Journal of chromatography. 1993 Nov; 621(2):225-9. doi: 10.1016/0378-4347(93)80099-p. [PMID: 8294544]
  • M Murai-Kushiya, S Okada, T Kimura, R Hasegawa. Effects of turpentine oil pretreatment on beta-blocker pharmacokinetic parameters in rats. The Journal of pharmacy and pharmacology. 1993 Sep; 45(9):836-8. doi: 10.1111/j.2042-7158.1993.tb05696.x. [PMID: 7903375]
  • R E Schmieder, J K Rockstroh, H G Münch, H Rüddel, H Schlebusch. Elevated serum activity of N-acetyl-beta-glucosaminidase in essential hypertension: diagnostic value and reversal to normal values after antihypertensive therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1991 Dec; 18(6):638-48. doi: 10.1016/s0272-6386(12)80603-2. [PMID: 1962647]
  • P K Gupta, J K Lim, A R Zoest, F C Lam, C T Hung. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state. Biopharmaceutics & drug disposition. 1991 Oct; 12(7):493-503. doi: 10.1002/bdd.2510120703. [PMID: 1932612]
  • J H Howard, P A Rechnitzer, D A Cunningham, D Wong, H Brown. Personality. Type A behavior, and the effects of beta-blockade. Journal of cardiovascular pharmacology. 1991 Aug; 18(2):267-77. doi: 10.1097/00005344-199108000-00014. [PMID: 1717789]
  • W P Gluth, F Sörgel. Determination of oxprenolol and its glucuronide metabolite in plasma and urine using high-performance liquid chromatography. Die Pharmazie. 1991 May; 46(5):336-9. doi: NULL. [PMID: 1896479]
  • T Ikeda, K Fujiyama, T Hoshino, Y Tanaka, T Takeuchi, H Mashiba, M Tominaga. Acute effect of thyroid hormone on insulin secretion in rats. Biochemical pharmacology. 1990 Oct; 40(8):1769-71. doi: 10.1016/0006-2952(90)90354-n. [PMID: 2242013]
  • Iu Iu Rugenius, R A Damiĭonaĭtene, Z Z Kuchinskene, A I Vidugiris, R V Steponenene. [Changes in lipid fractions of blood during the treatment of hypertension with prazosin and trasicor]. Kardiologiia. 1990 Jul; 30(7):14-5. doi: NULL. [PMID: 2232454]
  • L Kayser, H Perrild, P H Petersen, L Skovsted, J E Hansen. Acute beta-blockade changes the extracellular distribution of thyroid hormones. Journal of endocrinological investigation. 1990 Apr; 13(4):277-81. doi: 10.1007/bf03349560. [PMID: 1695234]
  • G Kakuk, G Kurta, I Kárpáti, J Mátyus. Use of tensiomin (captopril) in the antihypertensive treatment of haemodialysis patients. Therapia Hungarica (English edition). 1990; 38(2):71-6. doi: NULL. [PMID: 2198678]
  • R Jonkers, C J van Boxtel, R P Koopmans, B Oosterhuis. A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. The Journal of pharmacology and experimental therapeutics. 1989 Apr; 249(1):297-302. doi: NULL. [PMID: 2565392]
  • K P Devi, K V Rao, S Baveja, M Fathi, M Roth. Zero-order release formulation of oxprenolol hydrochloride with swelling and erosion control. Pharmaceutical research. 1989 Apr; 6(4):313-7. doi: 10.1023/a:1015998424548. [PMID: 2748519]
  • A O Obel. Effects of chlorthalidone, oxprenolol, and their combination in hypertensive blacks: a randomized double-blind crossover study. Journal of cardiovascular pharmacology. 1989 Mar; 13(3):465-70. doi: 10.1097/00005344-198903000-00016. [PMID: 2471894]
  • S S Davis, N Washington, G D Parr, A H Short, V A John, P Lloyd, S M Walker. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. British journal of clinical pharmacology. 1988 Oct; 26(4):435-43. doi: 10.1111/j.1365-2125.1988.tb03403.x. [PMID: 3056482]
  • A Gonzalez-Gomez, M Cires Pujols, F Gamio Capestany, A Rodriguez de la Vega, D Garcia-Barreto. Relationships between verapamil plasma concentrations and its antihypertensive action. International journal of clinical pharmacology, therapy, and toxicology. 1988 Sep; 26(9):453-60. doi: NULL. [PMID: 3198301]
  • N F Fraeyman, C D Dello, F M Belpaire. Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. British journal of clinical pharmacology. 1988 Jun; 25(6):733-40. doi: 10.1111/j.1365-2125.1988.tb05260.x. [PMID: 3203044]
  • G T McInnes, M J Brodie. Concentration-effect relationships for oxprenolol in patients with essential hypertension. British journal of clinical pharmacology. 1988 May; 25(5):539-45. doi: 10.1111/j.1365-2125.1988.tb03343.x. [PMID: 3408634]
  • K P Devi, K V Rao, S K Baveja, M Fathi, M Roth. Determination of oxprenolol in plasma by column liquid chromatography. Journal of chromatography. 1988 Apr; 426(1):229-33. doi: 10.1016/s0378-4347(00)81949-0. [PMID: 3384876]
  • C P Dello, F M Belpaire, A De Rick, N H Fraeyman. Influence of inflammation on serum concentration, molecular heterogeneity and drug binding properties of canine alpha-1-acid glycoprotein. Journal of veterinary pharmacology and therapeutics. 1988 Mar; 11(1):71-6. doi: 10.1111/j.1365-2885.1988.tb00123.x. [PMID: 3379666]
  • R Koopmans, B Oosterhuis, J M Karemaker, J Wemer, C J van Boxtel. Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring. European journal of clinical pharmacology. 1988; 34(4):395-400. doi: 10.1007/bf00542442. [PMID: 3402525]
  • F M Belpaire, E J Van de Velde, N H Fraeyman, M G Bogaert, N Lameire. Influence of continuous ambulatory peritoneal dialysis on serum alpha 1-acid glycoprotein concentration and drug binding. European journal of clinical pharmacology. 1988; 35(4):339-43. doi: 10.1007/bf00561361. [PMID: 3197741]
  • G T McInnes, M J Brodie. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension. European journal of clinical pharmacology. 1988; 34(6):605-11. doi: 10.1007/bf00615225. [PMID: 3169112]
  • D G McDevitt. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. European heart journal. 1987 Dec; 8 Suppl M(?):9-14. doi: 10.1093/eurheartj/8.suppl_m.9. [PMID: 2897304]
  • R Jonkers, C J Van Boxtel, B Oosterhuis. Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol. Clinical pharmacology and therapeutics. 1987 Dec; 42(6):627-33. doi: 10.1038/clpt.1987.210. [PMID: 2826064]
  • C P Dello, F M Belpaire, J A Kint, N H Fraeyman. Dog alpha-1-acid glycoprotein: purification and biochemical characterization. Journal of pharmacological methods. 1987 Dec; 18(4):335-45. doi: 10.1016/0160-5402(87)90065-9. [PMID: 3695542]
  • J Godbillon, N Vidon, R Palma, A Pfeiffer, C Franchisseur, M Bovet, G Gosset, J J Bernier, J Hirtz. Jejunal and ileal absorption of oxprenolol in man: influence of nutrients and digestive secretions on jejunal absorption and systemic availability. British journal of clinical pharmacology. 1987 Sep; 24(3):335-41. doi: 10.1111/j.1365-2125.1987.tb03178.x. [PMID: 3663450]
  • G Pflugmann, H Spahn, E Mutschler. Rapid determination of the enantiomers of metoprolol, oxprenolol and propranolol in urine. Journal of chromatography. 1987 May; 416(2):331-9. doi: 10.1016/0378-4347(87)80516-9. [PMID: 3611264]
  • M R Gregg, D B Jack, S R Smith, M J Kendall. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration. Journal of clinical pharmacy and therapeutics. 1987 Apr; 12(2):91-9. doi: 10.1111/j.1365-2710.1987.tb00513.x. [PMID: 3584272]
  • F M Belpaire, A De Rick, C Dello, N Fraeyman, M G Bogaert. Alpha 1-acid glycoprotein and serum binding of drugs in healthy and diseased dogs. Journal of veterinary pharmacology and therapeutics. 1987 Mar; 10(1):43-8. doi: 10.1111/j.1365-2885.1987.tb00075.x. [PMID: 3586122]
  • F M Belpaire, B Chindavijak, M G Bogaert. SKF 525A displaces drugs from serum alpha 1-acid glycoprotein binding sites. The Journal of pharmacology and experimental therapeutics. 1987 Feb; 240(2):628-30. doi: . [PMID: 3806415]
  • C Harvengt, J P Desager, F Heller, R Hulhoven. Beta-blocking agents and plasma lipids: an update. Advances in experimental medicine and biology. 1987; 210(?):195-200. doi: 10.1007/978-1-4684-1268-0_28. [PMID: 2884823]
  • N Vidon, R Palma, J Godbillon, C Franchisseur, G Gosset, J J Bernier, J Hirtz. Gastric and intestinal absorption of oxprenolol in humans. Journal of clinical pharmacology. 1986 Nov; 26(8):611-5. doi: 10.1002/j.1552-4604.1986.tb02958.x. [PMID: 3793952]
  • H Perrild, U Feldt-Rasmussen, L Kayser, J Mølholm Hansen. Short-term beta-adrenergic blockade decreases serum thyroglobulin in hyper- and euthyroid patients. Journal of endocrinological investigation. 1986 Oct; 9(5):413-5. doi: 10.1007/bf03346953. [PMID: 2878948]
  • M J Antonaccio, J High, J M DeForrest, E Sybertz. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. The Journal of pharmacology and experimental therapeutics. 1986 Jul; 238(1):378-87. doi: . [PMID: 2873238]
  • F M Belpaire, M G Bogaert, P Mugabo, M T Rosseel. Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation. British journal of pharmacology. 1986 Jul; 88(3):697-705. doi: 10.1111/j.1476-5381.1986.tb10253.x. [PMID: 2874859]
  • I D Bradbrook, M Babiker, P Crome, H C Gillies, P J Morrison, H J Rogers, P Shotton. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects. British journal of clinical pharmacology. 1986 Apr; 21(4):371-6. doi: 10.1111/j.1365-2125.1986.tb05209.x. [PMID: 3707811]
  • W Dieterle, J W Faigle, W Küng, W Theobald. The disposition and metabolism of 14C-oxprenolol.HCl in man. Xenobiotica; the fate of foreign compounds in biological systems. 1986 Feb; 16(2):181-91. doi: 10.3109/00498258609043521. [PMID: 3515777]
  • K Szabó, M Faragó, I Balogh, A Gergely, G Rubányi, A G Kovách. The effect of alpha and beta adrenergic blockade on Ni induced coronary spasm in scalded rats. Acta physiologica Hungarica. 1986; 68(2):129-45. doi: NULL. [PMID: 3825550]
  • C I Backhouse, D Rowley-Jones, L Spencer-Mills. Hydrochlorothiazide and triamterene with sustained-release oxprenolol in the treatment of hypertension. Current medical research and opinion. 1986; 10(3):196-202. doi: 10.1185/03007998609110438. [PMID: 3731824]
  • M Prinoth, H Spahn, E Mutschler. The development of reliable compliance tests for antihypertensive drugs. European journal of clinical pharmacology. 1986; 29(5):535-9. doi: 10.1007/bf00635889. [PMID: 3956559]
  • J Godbillon, M Duval, G Gosset. Determination of oxprenolol in human plasma by high-performance liquid chromatography, in comparison with gas chromatography and gas chromatography-mass spectrometry. Journal of chromatography. 1985 Dec; 345(2):365-71. doi: 10.1016/0378-4347(85)80173-0. [PMID: 4086604]
  • L Saunders, D Ingram, S J Warrington. The pharmacokinetics and dynamics of oxprenolol: a simulation study with six subjects. The Journal of pharmacy and pharmacology. 1985 Nov; 37(11):802-6. doi: 10.1111/j.2042-7158.1985.tb04971.x. [PMID: 2867161]
  • J Webster, J C Petrie, O J Robb, M Jamieson, J Verschueren. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients. British journal of clinical pharmacology. 1985 Oct; 20(4):393-400. doi: 10.1111/j.1365-2125.1985.tb05083.x. [PMID: 2866786]
  • J W Rigby, A K Scott, G M Hawksworth, J C Petrie. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. British journal of clinical pharmacology. 1985 Oct; 20(4):327-31. doi: 10.1111/j.1365-2125.1985.tb05072.x. [PMID: 2866783]
  • K Takeda, E Kusano, Y Asano, S Hosoda. Beta-antagonist and secondary hyperparathyroidism in chronic renal failure. Nihon Jinzo Gakkai shi. 1985 Sep; 27(9):1299-304. doi: NULL. [PMID: 4087550]
  • D Gaudry, D Wantiez, J P Metayer, J Richard. Simultaneous determination of oxprenolol and 2H6-labelled oxprenolol in human plasma by gas chromatography/mass spectrometry. Biomedical mass spectrometry. 1985 Jun; 12(6):269-73. doi: 10.1002/bms.1200120605. [PMID: 3160404]
  • O Petkov, V Orbetsova, L Dakovska. Changes in blood plasma and myocardial lipids in experimental thyrotoxic myocardial hypertrophy in rabbits. Cor et vasa. 1985; 27(6):464-72. doi: NULL. [PMID: 4092475]
  • M Sznajderman, I Cybulska, J Niegowska, Z Zawadzki, M Sznajderman. [Effect of 3-month treatment with propranolol, oxprenolol, metoprolol and pindolol on plasma lipids and lipoproteins in patients with primary arterial hypertension]. Kardiologia polska. 1985; 28(7):489-99. doi: NULL. [PMID: 2868145]
  • A Racine-Poon, J Moppert. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):143S-149S. doi: 10.1111/j.1365-2125.1985.tb02755.x. [PMID: 4005116]
  • D B Jack, M J Kendall, S J Laugher, S R Smith. Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):185S-190S. doi: 10.1111/j.1365-2125.1985.tb02760.x. [PMID: 4005121]
  • J Moppert, P H Degen, A Racine-Poon. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):197S-201S. doi: 10.1111/j.1365-2125.1985.tb02762.x. [PMID: 2988591]
  • I D Bradbrook, V A John, P J Morrison, H J Rogers, R G Spector. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):163S-169S. doi: 10.1111/j.1365-2125.1985.tb02757.x. [PMID: 4005118]
  • K L Woods, D B Jack, M J Kendall, A Halsey, M L O'Donnell, S J Warrington, V A John. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):177S-184S. doi: 10.1111/j.1365-2125.1985.tb02759.x. [PMID: 4005120]
  • P N Bennett, J Bennett, I Bradbrook, J Francis, V A John, H Rogers, P Turner, S J Warrington. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):171S-175S. doi: 10.1111/j.1365-2125.1985.tb02758.x. [PMID: 4005119]
  • J M Cruickshank, G Neil-Dwyer. Beta-blocker brain concentrations in man. European journal of clinical pharmacology. 1985; 28 Suppl(?):21-3. doi: 10.1007/bf00543705. [PMID: 2865144]
  • K H Antonin, P Bieck, M Scheurlen, M Jedrychowski, H Malchow. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):137S-142S. doi: 10.1111/j.1365-2125.1985.tb02754.x. [PMID: 4005115]
  • F Langenbucher, J Mysicka. In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):151S-162S. doi: 10.1111/j.1365-2125.1985.tb02756.x. [PMID: 4005117]
  • V A John, S E Smith. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. British journal of clinical pharmacology. 1985; 19 Suppl 2(?):191S-195S. doi: 10.1111/j.1365-2125.1985.tb02761.x. [PMID: 4005122]
  • P Sassano, G Chatellier, A M Amiot, F Alhenc-Gelas, P Corvol, J Ménard. A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1984 Dec; 2(2):S75-80. doi: NULL. [PMID: 6100880]
  • C Delcroix, N Fraeyman, F Belpaire. A method for the assay of alpha 1-acid glycoprotein in dog serum and its application to the plasma binding of propranolol and oxprenolol in animals receiving rifampicin. Journal of pharmacological methods. 1984 Sep; 12(2):97-105. doi: 10.1016/0160-5402(84)90027-5. [PMID: 6536820]